Benitec Biopharma Inc (BNTC) Stock AnalysisBNTCBenitec Biopharma Inc

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Benitec Biopharma Inc (BNTC) appears to be a good buy right now due to its current price of $12.47, which is significantly below the analyst price targets of $16 and $25. The company has a strong cash position of approximately $184.8 million, which supports its ongoing clinical trials and reduces funding risks. However, the main risk is its negative earnings trend, with a net loss of $11.9 million reported in Q3 2026, indicating ongoing financial challenges.

1 analysts cover BNTC: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.00.